Meeting Impression | Managing Diabetes & CVD: Is epigenetics a new way forward?August 26, 2017 - ESC
See below to download the Meeting Impression
The aim of this educational program was to provide a summary of the epidemiology and pathophysiology of patients at high cardiovascular (CV) risk with diabetes (DM), and to understand the origin of the high residual CV risk in patients with DM. Moreover, an objective was to review how BET inhibition could serve as a novel strategy to improve outcomes in CVD. BET refers to a bromodomain and extra-terminal domain of regulatory proteins. Its inhibition modifies gene expression via epigenetic mechanisms. Current clinical research programs evaluating the role of epigenetic regulation of gene expression in CVD management were reviewed.
This symposium was held during the ESC Congress in Barcelona, Spain on August 26, 2017. It was chaired by Kausik Ray (Imperial College London, UK) and Lina Badimon (Cardiovascular Research Center, Barcelona, Spain).
The educational objectives of this symposium were to:
- To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
- To understand the origin of the high residual cardiovascular risk in patients with diabetes, ACS
- To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD
- To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
-Prof. Kausik Ray - London, United Kingdom : Managing high risk diabetes patient with cardiovascular disease: What works, and what else can we do?
-Prof. Erik Stroes - Amsterdam, The Netherlands : Promise of epigenetic modulation as a target in atherosclerotic patients
-Prof. Stephen Nicholls - Adelaide, Australia : Insights from the first trials in epigenetics in human: What is the way forward?
Prof Nicholls disclosed the following related to this presentation- Research support: AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience - Consulting and honoraria: AstraZeneca, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim
This symposium was supported by an unrestricted educational grant provided by Resverlogix.